在B细胞缺乏症患者中对基于的COVID-19T细胞激活剂进行I/II期试验

Jonas S Heitmann1,2, Claudia Tandler2,3,4, Maddalena Marconato1,2

  • 1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.

Nature communications
|August 18, 2023
PubMed
概括

CoVac-1是一种基于的激活剂,在B细胞缺乏症患者中有效诱导强大的SARS-CoV-2T细胞免疫力. 这种COVID-19 T细胞疗法表现出良好的安全性,需要进一步的临床评估.